Quest Diagnostics Inc. has joined the competitive field of BRCA diagnostic testing for the risk of inherited breast or ovarian cancer with the BRCAvantage genetic test, launched Oct. 15.
Quest’s said it planned to launch a BRCA diagnostic test soon after the Supreme Court ruled in June that Myriad Genetics Inc. patents on the BRCA1 and BRCA2 genes...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?